ARTICLE | Clinical News

Shire Fosrenol extension data

June 10, 2003 7:00 AM UTC

Shire (LSE:SHP; SHPGY) said that in an open-label extension of a 6-month European Phase III study of Fosrenol lanthanum carbonate to treat end-stage renal disease, serum phosphorus was maintained throughout the study in 68.9% (31/46) of patients after 3 years and 71.7% (33/46) of patients after 1 year. The subgroup of 46 dialysis patients from the 767-patient trial completed at least 36 months of treatment with Fosrenol. Also, there were no differences in the incidence or types of adverse events seen throughout the study in the long-term exposure patients. There was a low incidence of hypercalcemia. ...